US EditionPublished • loading... • Updated
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $40.00 at The Goldman Sachs Group
Multiple brokerages raised Denali Therapeutics' price targets following FDA approval for AVLAYAH, with Goldman Sachs increasing its target to $40, reflecting strong analyst confidence.
Summary by defenseworld.net
1 Articles
1 Articles
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $40.00 at The Goldman Sachs Group
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price boosted by The Goldman Sachs Group from $35.00 to $40.00 in a report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock. A number of other research analysts also recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of Denali Therapeutics from $29.00 to $32.00 and gave the stock an “outperform” ra…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
